MESO vs VIR: stock comparison and AI forecast
Mesoblast Ltd (MESO) and Vir Biotechnology, Inc. (VIR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MESO Mesoblast Ltd
- Price
- $14.54 -9.1% · 6M
- Market Cap
- $1.86B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
VIR Vir Biotechnology, Inc.
- Price
- $11.75 +15.0% · 6M
- Market Cap
- $1.99B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- MESO and VIR have similar market capitalizations ($1.86B and $1.99B).
- Over the last six months VIR returned +15.0% and MESO -9.1%.
- MESO carries 0.36 times debt per unit of equity, against 0.24 times for VIR.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MESO | VIR |
|---|---|---|
| Market Cap | $1.86B | $1.99B |
| P/B Ratio | – | 2.02x |
| EPS | $-0.25 | $-1.89 |
| Book Value/Share | – | $5.81 |
| Revenue/Share | $0.61 | – |
| FCF/Share | – | $-1.20 |
Profitability & Margins
| Metric | MESO | VIR |
|---|---|---|
| ROE | – | -25.6% |
| ROA | – | -20.7% |
| ROIC | – | -25.0% |
| Gross Margin | – | 83.7% |
| Operating Margin | – | -76.3% |
| Net Margin | – | -68.5% |
| EBT Margin | -357.5% | -68.4% |
| Tax Rate | -0.3% | -0.1% |
Financial Health
| Metric | MESO | VIR |
|---|---|---|
| Current Ratio | 1.58x | 6.04x |
| Quick Ratio | 1.41x | – |
| D/E Ratio | 0.36x | 0.24x |
| Financial Leverage | 1.36x | 1.24x |
| Working Capital | $74M | $479M |
Cash Flow
| Metric | MESO | VIR |
|---|---|---|
| Operating Cash Flow | -$149M | -$203M |
| Free Cash Flow | – | -$204M |
| Capital Spending | – | -$1M |
Operational Efficiency
| Metric | MESO | VIR |
|---|---|---|
| Asset Turnover | 0.10x | – |
| Receivables Turnover | 1.8x | – |
| Fixed Assets Turnover | 43.3x | – |
| Days Sales Outstanding | 204 days | – |
| Payables Period | – | 249239 days |
Income Statement
| Metric | MESO | VIR |
|---|---|---|
| Total Revenue | $78M | – |
| Operating Income | – | -$280M |
| Net Income | – | -$252M |
| R&D Expense | $127M | $484M |
| SG&A Expense | – | $99M |
| Cost of Goods Sold | – | $30K |
Dividend & Shareholder Information
| Metric | MESO | VIR |
|---|---|---|
| Shares Outstanding | 128M | 169M |
MESO vs VIR: stock comparison and AI forecast
Which is bigger, MESO or VIR?
MESO and VIR have similar market capitalizations ($1.86B and $1.99B).
Which stock performed better over the last six months, MESO or VIR?
Over the last six months VIR returned +15.0% and MESO -9.1%.
Which one does Intratio's AI model rank higher, MESO or VIR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.